Equities

Bioton SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Bioton SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)4.04
  • Today's Change0.02 / 0.50%
  • Shares traded26.64k
  • 1 Year change+8.17%
  • Beta0.5081
Data delayed at least 15 minutes, as of Feb 12 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

  • Revenue in PLN (TTM)295.81m
  • Net income in PLN-2.82m
  • Incorporated2004
  • Employees363.00
  • Location
    Bioton SAul. Staroscinska 5WARSZAWA 02-516PolandPOL
  • Phone+48 227214000
  • Fax+48 227211333
  • Websitehttps://bioton.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Genomtec SA15.00k-11.01m77.28m----7.47--5,152.11-0.7485-0.74850.0010.68690.0009--0.0143---65.47-89.96-82.11-113.38-54,120.00-4,379.72-73,393.34-17,225.072.82-39.820.1409--0.00-63.42-24.35---34.54--
Hyenergy SA3.29m169.85k77.91m27.00--3.95318.9023.69-0.0936-0.09360.16540.58780.18210.12590.7741--0.94032.391.283.3599.7077.465.163.111.301.170.00--192.8319.47100.30---45.79--
Urteste SA0.00-5.47m78.75m34.00--3.36-----3.88-3.880.0015.350.00-------15.56-29.65-18.99-31.35---45,933.33---623,333.30----0.0128------35.00--197.79--
Nanogroup SA-6.90k-6.93m85.19m----7.30-----0.1844-0.1844-0.00020.3553-0.00032.64-----30.59-29.50-51.55-33.80--66.72---2,258.260.9785-464.180.00--3.96-64.0934.50--3.07--
Poltreg SA0.00-24.56m128.24m33.00--2.59-----5.27-5.270.0010.610.0016.45--0.00-25.87-9.02-29.62-10.18---659.36---854.232.65--0.1365---74.98-6.89-38.06--83.47--
Mabion SA14.81m-59.30m133.02m204.00--1.90--8.98-3.67-3.670.91644.330.09888.1027.2572,602.94-39.560.5366-54.811.06-178.5558.34-400.370.96430.2276--0.04---54.50---115.35--6.00--
Molecure SA5.11m-24.42m152.46m71.00--1.70--29.82-1.20-1.200.24934.340.0553--7.0150,119.41-26.42-3.15-27.53-3.3051.4893.34-477.67-15.45----0.0588---40.47278.20-10.27--12.49--
BIOTON SA295.81m-2.82m346.89m363.00--0.58599.811.17-0.0329-0.03293.456.900.38142.028.84814,906.30-0.36380.5935-0.43250.733829.6941.35-0.9542.470.51861.640.06820.0014.380.561-788.26---26.87--
Scope Fluidics SA718.00k54.47m456.23m132.007.203.408.08635.4219.9919.990.263342.350.00650.934810.8011,396.8349.2554.4452.7958.98-178.69-440.537,586.7733,272.1212.82--0.0212---74.61--448.26--5.75--
Captor Therapeutics SA7.57m-40.71m460.93m91.00--13.79--60.89-7.68-7.681.436.020.1387--4.2783,186.81-74.58-43.62-102.84-55.6265.3265.95-537.79-450.96----0.1029--19.88--45.56--13.11--
Ryvu Therapeutics SA69.80m-118.69m590.72m294.00--8.29--8.46-5.13-5.133.023.080.21212.297.31237,411.60-36.05-23.64-48.51-27.8470.8629.35-170.05-208.852.26--0.572--66.3883.01-20.98---24.46--
Selvita SA373.90m-2.89m807.64m434.00--2.5515.292.16-0.1577-0.157720.3717.230.59838.964.97398,187.40-0.46295.76-0.57157.3380.2780.65-0.77378.570.88230.75380.3757---1.73---108.73------
Data as of Feb 12 2026. Currency figures normalised to Bioton SA's reporting currency: Polish New Zloty PLN

Institutional shareholders

0.58%Per cent of shares held by top holders
HolderShares% Held
AgioFunds TFI SAas of 30 Dec 2025254.41k0.30%
Dimensional Fund Advisors LPas of 08 Jan 2026238.03k0.28%
SSgA Funds Management, Inc.as of 08 Jan 20261.70k0.00%
DFA Australia Ltd.as of 30 Nov 20251.34k0.00%
ANIMA Sgr SpAas of 30 Jun 20251.000.00%
Dimensional Fund Advisors Ltd.as of 30 Nov 20250.000.00%
More ▼
Data from 30 Sep 2025 - 08 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.